Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 16/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69827 | 1.00 | SCD (0.45) | SCDSMN1; SMN2P2RY12 | |
| SCHEMBL69974 | 0.90 | SCD (0.45) | SCDSMN1; SMN2P2RY12 | |
| SCHEMBL29385059 | 0.90 | SCD (0.45) | SCDSMN1; SMN2P2RY12 | |
| SCHEMBL29384732 | 0.90 | SCD (0.47) | SCDSMN1; SMN2P2RY12 | |
| SCHEMBL69318 | 0.90 | SCD (0.47) | SCDSMN1; SMN2P2RY12 | |
| SCHEMBL68763 | 0.89 | SCD (0.51) | SCDSMN1; SMN2P2RY12 | |
| SCHEMBL69783 | 0.89 | SCD (0.57) | SCD | |
| SCHEMBL70454 | 0.89 | SCD (0.49) | SCDP2RY12 | |
| SCHEMBL29384277 | 0.89 | SCD (0.48) | SCDP2RY12 | |
| SCHEMBL70356 | 0.89 | SCD (0.48) | SCDP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | SCD 1194/4885SMN1; SMN2 7/4885P2RY12 2448/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SCD 1194/4885SMN1; SMN2 7/4885P2RY12 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.